BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...of clinical operations; she held the same role at MC2 Therapeutics A/S. Drug delivery play Enteris BioPharma Inc....
...Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier Healthcare Partners Horama S.A. Nordic Nanovector ASA Personalis Inc. Centogene Acesion Pharma ApS Enteris BioPharma Inc. Lifemax...
BioCentury | Feb 3, 2017
Company News

Enteris, Ferring deal

...Enteris granted Ferring exclusive, worldwide rights to Enteris' oral drug delivery technologies, including Peptelligence, to develop...
...and commercialize an oral formulation of an undisclosed peptide-based injectable therapeutic for an undisclosed indication. Enteris...
...additional details. Enteris BioPharma Inc. , Boonton, N.J. Ferring Pharmaceuticals A/S , Saint-Prex, Switzerland Business: Drug delivery Nora Weintraub Enteris BioPharma Inc. Ferring...
BioCentury | Aug 1, 2016
Clinical News

Oral Tobrate tobramycin: Phase I started

...trial to evaluate single and multiple ascending doses of oral Tobrate in 24 healthy volunteers. Enteris BioPharma Inc....
BioCentury | Jan 20, 2016
Company News

Management tracks

...Drug delivery play Enteris BioPharma Inc. (Boonton, N.J.) named Joel Tune CEO and promoted Paul Shields to COO...
...Joel Tune CEO and promoted Paul Shields to COO from VP of operations. Tune was Enteris'...
BioCentury | Nov 9, 2015
Clinical News

Oral salmon calcitonin regulatory update

...developed with Enteris’ oral delivery technology (see BioCentury, Oct. 26, 2009 & May 27, 2013). Enteris BioPharma Inc....
BioCentury | Dec 22, 2014
Clinical News

Oral CR845: Phase I data

...events reported. The oral tablet formulation of CR845 was developed using peptide formulation technology from Enteris BioPharma Inc....
BioCentury | Jul 14, 2014
Clinical News

Oral CR845: Phase I started

...CR845 in up to 150 healthy volunteers. Oral CR845 contains a peptide formulation technology from Enteris BioPharma Inc....
BioCentury | Oct 7, 2013
Company News

Enteris, Nordic Bioscience deal

...Enteris BioPharma granted Nordic Bioscience's KeyBioScience subsidiary rights to Enteris' Peptelligence oral drug delivery and recombinant...
...drug delivery and recombinant manufacturing technologies for the development of a family of metabolic peptides. Enteris...
...of preclinical and clinical trial API and solid dosage form finished product. Under the deal, Enteris...
BioCentury | Aug 12, 2013
Company News

Enteris BioPharma Inc. management update

...Brian Zietsman as president and CFO, formerly CFO of Unigene Enteris BioPharma Inc. , Boonton, N.J. Business: Drug...
BioCentury | May 27, 2013
Company News

Unigene deal

...II and VPC Intermediate Fund II, then transferred the assets to Victory Park Capital affiliate Enteris BioPharma Inc....
Items per page:
1 - 10 of 12
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...of clinical operations; she held the same role at MC2 Therapeutics A/S. Drug delivery play Enteris BioPharma Inc....
...Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier Healthcare Partners Horama S.A. Nordic Nanovector ASA Personalis Inc. Centogene Acesion Pharma ApS Enteris BioPharma Inc. Lifemax...
BioCentury | Feb 3, 2017
Company News

Enteris, Ferring deal

...Enteris granted Ferring exclusive, worldwide rights to Enteris' oral drug delivery technologies, including Peptelligence, to develop...
...and commercialize an oral formulation of an undisclosed peptide-based injectable therapeutic for an undisclosed indication. Enteris...
...additional details. Enteris BioPharma Inc. , Boonton, N.J. Ferring Pharmaceuticals A/S , Saint-Prex, Switzerland Business: Drug delivery Nora Weintraub Enteris BioPharma Inc. Ferring...
BioCentury | Aug 1, 2016
Clinical News

Oral Tobrate tobramycin: Phase I started

...trial to evaluate single and multiple ascending doses of oral Tobrate in 24 healthy volunteers. Enteris BioPharma Inc....
BioCentury | Jan 20, 2016
Company News

Management tracks

...Drug delivery play Enteris BioPharma Inc. (Boonton, N.J.) named Joel Tune CEO and promoted Paul Shields to COO...
...Joel Tune CEO and promoted Paul Shields to COO from VP of operations. Tune was Enteris'...
BioCentury | Nov 9, 2015
Clinical News

Oral salmon calcitonin regulatory update

...developed with Enteris’ oral delivery technology (see BioCentury, Oct. 26, 2009 & May 27, 2013). Enteris BioPharma Inc....
BioCentury | Dec 22, 2014
Clinical News

Oral CR845: Phase I data

...events reported. The oral tablet formulation of CR845 was developed using peptide formulation technology from Enteris BioPharma Inc....
BioCentury | Jul 14, 2014
Clinical News

Oral CR845: Phase I started

...CR845 in up to 150 healthy volunteers. Oral CR845 contains a peptide formulation technology from Enteris BioPharma Inc....
BioCentury | Oct 7, 2013
Company News

Enteris, Nordic Bioscience deal

...Enteris BioPharma granted Nordic Bioscience's KeyBioScience subsidiary rights to Enteris' Peptelligence oral drug delivery and recombinant...
...drug delivery and recombinant manufacturing technologies for the development of a family of metabolic peptides. Enteris...
...of preclinical and clinical trial API and solid dosage form finished product. Under the deal, Enteris...
BioCentury | Aug 12, 2013
Company News

Enteris BioPharma Inc. management update

...Brian Zietsman as president and CFO, formerly CFO of Unigene Enteris BioPharma Inc. , Boonton, N.J. Business: Drug...
BioCentury | May 27, 2013
Company News

Unigene deal

...II and VPC Intermediate Fund II, then transferred the assets to Victory Park Capital affiliate Enteris BioPharma Inc....
Items per page:
1 - 10 of 12